Trustees press insurer on Ozempic, Manjaro coverage and prior‑authorization rules
Board members sought clarity about how the district's pharmacy manager handles semaglutide drugs and step‑therapy; Blue Cross said prior authorization and step therapy apply for new patients, and that ~370 members are currently on semaglutide-type medications.
The full story
Trustees pressed Blue Cross Blue Shield staff and the district's risk office for specifics about pharmacy management of high-cost GLP‑1 drugs such as Ozempic and Manjaro amid national attention on specialty therapies.
Sign up to keep reading.
Your free newsletter brings you what your city council, county, and school board discussed and decided.
or